

The Circadian Clock in the Kidney

Lisa R. Stow* and Michelle L. Gumz†

*Biochemistry and Molecular Biology and †Medicine, Division of Nephrology, Hypertension and Renal Transplantation, University of Florida, Gainesville, Florida

ABSTRACT

Circadian variations in renal function were first described in the 19th century, and GFR, renal blood flow, urine production, and electrolyte excretion exhibit daily oscillations. These clinical observations are well established, but the underlying mechanisms that govern circadian fluctuations in kidney are not fully understood. Here we provide a brief overview of the machinery governing the circadian clock and examine the clinical and molecular evidence supporting a critical role for circadian rhythm in the kidney. There is a connection between BP oscillation and renal disease that supports the use of chronotherapy in the treatment of hypertension or correction of nondipping BP. Such studies support a developing model of clock controlled sodium and water transport in renal epithelial cells. Recent advances in identifying novel clock-controlled genes using rodent and cellular models also shed light on the molecular mechanisms by which the circadian clock controls renal function; however, the field is new and much more work remains.

J Am Soc Nephrol 22: 598–604, 2011. doi: 10.1681/ASN.2010080803

Most physiologic processes, including sleep-wake patterns, heartbeat, and systemic arterial BP, exhibit a circadian pattern of variation. The word circadian is derived from the Latin words *circa* and *dies*, meaning about a day. The term circadian is used here to denote biologic processes that occur with a daily, or approximately a 24-hour rhythm. A more stringent definition of circadian is used in studies of biologic rhythms to describe oscillations that occur under constant conditions; a process is considered truly circadian only if the oscillation is maintained in the absence of external zeitgebers, or time cues such as light/dark cycles. It has been over a century since Vogel first reported daily fluctuations in urine volume.¹ Healthy individuals excrete more electrolytes and produce more urine during the day than at night, and there are diurnal rhythms for urinary sodium, potassium, and chloride excretion.² Disruption of these patterns is often associated with hypertension and cardiovascular disease.^{3,4}

The master pacemaker of the circadian clock is located in the suprachiasmatic nucleus (SCN) of the brain. This central clock is entrained by light signals transmitted from the retina through the retinohypothalamic tract. A core group of clock genes functions in a series of transcription-based feedback loops (Figure 1). Transcription factors, Bmal1 and Clock, drive the transcription of the Period (*Per1*, 2, and 3) and Cryptochrome (*Cry1* and 2) genes and nuclear receptor genes, *ROR* and *Rev-erba*. The Bmal1/Clock heterodimer regulates gene expression by binding E-box response elements (CANNTG) in the promoter region of target genes. Period and Cryptochrome inhibit Bmal1 and Clock action, thereby repressing their own transcription, whereas ROR and Rev-erba mediate opposing action on Bmal1 expression.^{5,6} Post-translational modification controls stability and nuclear entry of clock proteins, contributes to the precise timing of the clock mechanism, and is

thought to allow crosstalk between physiology and the clock.^{5,7} In addition to regulating each other to maintain oscillation, the core clock proteins regulate genes that mediate physiologic functions governed by circadian rhythm. These clock-controlled output genes constitute up to 15% of expressed transcripts in some tissues.⁸

The core clock machinery has been identified in nearly every peripheral tissue. The master clock in the SCN synchronizes the functions of these peripheral clocks through neuronal and humoral signaling.⁹ As well, body temperature, rest-activity cycles, and feeding cycles contribute to entrainment of the peripheral clocks. Although the relationship between the central and peripheral clocks has been described as co-dependent, the peripheral clocks do not respond identically to cues from the SCN.^{10–12} Thus, study of the clock in individual tissues is necessary. The role of circadian rhythms has recently been reviewed for the cardiovascular system,¹³ the vasculature,^{14,15} metabolic syndrome,¹⁶ and the gastrointestinal system.¹⁷ Here we examine the clinical and molecular evidence supporting a critical role for the clock in the control of renal function.

Published online ahead of print. Publication date available at www.jasn.org.

Correspondence: Dr. Michelle L. Gumz, 1600 SW Archer Road, Box 100224, Gainesville, FL 32610. Phone: 352-273-6887; Fax: 352-392-3581; E-mail: Michelle.Gumz@medicine.ufl.edu

Copyright © 2011 by the American Society of Nephrology




Figure 1. Transcriptional mechanism of the circadian clock. Bmal1 and Clock heterodimerize to positively regulate expression of the *Period* (*per*) and *Cryptochrome* (*cry*) gene families, as well as the retinoic acid orphan receptor (*ror*) and *Nr1d1* (*rev-erba*) genes. Per/Cry inhibit Bmal1/Clock action to repress their own transcription, whereas ROR and Rev-erba mediate opposing action on *bmal1* gene expression. Expression of the Clock protein is constitutive in many tissues. Bmal1/Clock action is mediated through binding of E-box response elements (CANNTG) in the promoters of target genes.

ROLE OF THE CIRCADIAN CLOCK IN THE KIDNEY: CLINICAL EVIDENCE

Nondipping BP and the Kidney

Cardiovascular events such as stroke and myocardial infarction are known to peak with the morning surge in BP and heart rate. BP increases in the early morning, followed by a plateau during the day, and then dips during sleep.¹⁸ Patients who do not exhibit a 10 to 20% decrease in nighttime *versus* daytime BP are designated “nondippers” and are at increased risk of cardiac death.¹⁹ Nondippers exhibit increased left ventricular hypertrophy, carotid artery wall thickness and atherosclerotic plaques, microalbuminuria, cerebrovascular disease, congestive heart failure, vascular dementia, stroke, and myocardial infarction.²⁰ Importantly, nondipping may predict renal damage.²¹

Several reports link aldosterone signaling to the disruption of circadian BP patterns, suggesting a role for renal function in maintaining normal circadian

changes in BP. Patients suffering from aldosteronism exhibit the nondipper pattern,^{22,23} and treatment with the angiotension II receptor blocker, irbesartan corrects the nondipper pattern in salt-sensitive hypertension.²⁴ The diuretic hydrochlorothiazide restores an appropriate decrease in nocturnal BP in nondipping patients but had no effect in dippers.²⁵ Furthermore, dietary sodium restriction re-establishes the nocturnal dipping pattern.²⁶ Nondipping associates with an increased risk of nephropathy²⁷ and chronic kidney disease.²⁸ Importantly, renal transplantation can rescue the nondipping phenotype,²⁹ although a lack of nocturnal variation can portend poor allograft survival.³⁰ Collectively, these findings suggest a direct link between abnormal circadian patterns in BP and inappropriate sodium transport in the kidney.

Salt handling by the kidney has long been recognized as a critical determinant of BP, and hypertension is rarely observed in the absence of renal dysfunction.³¹ A decline in renal function di-

rectly correlates with a nondipping phenotype. A well-controlled study showed that creatinine clearance declines more rapidly in nondippers compared with dippers, and urinary protein excretion is greater in the nondippers compared with dippers.³² The nondipping phenotype also associates with a faster decline in renal function, and the authors suggested that regulation of nocturnal BP should be an additional goal of anti-hypertensive treatment. Similarly, Agarwal and Light³³ determined that a nondipping status was a significant predictor of chronic kidney disease and proteinuria and inferred that correction of dipper status could be an effective therapy for kidney disease. Taken together, these studies showed the important relationship between renal physiology and the circadian pattern of BP.

Chronotherapy in the Treatment of Hypertension

Increasing evidence supports a critical role for the circadian clock in human health. Chronotherapy, the scheduled administration of pharmaceutical agents with respect to an individual’s circadian rhythms, may increase the effectiveness and decrease the side effects of pharmacologic agents.^{34,35} Chronotherapy has been investigated in the treatment of many nonrenal diseases^{36–40} and has been proposed for treatment of diabetes,⁴¹ cardiac arrhythmias,⁴² and ischemic heart disease.⁴³

The potential benefits of chronotherapy in the treatment of hypertension include control of BP and normalization of the dipping pattern.⁴⁴ Cross-sectional and longitudinal studies consistently show that nondipping is a preclinical marker for cardiovascular and renal disease and can be used to predict cardiovascular events.⁴⁵ Indeed, accruing evidence suggests that nighttime BP is a more important indicator of cardiovascular health than daytime values.^{46,47} One example comes from a convincing study in which previously untreated hypertensive patients were randomized into groups receiving a single daily dose of ramipril either in the morning or at bedtime.⁴⁸ BP during sleep was signifi-

cantly reduced in bedtime-dosed patients compared with morning-dosed patients. Notably, nighttime dosing also increases the effectiveness of ramipril as BP reduction lasted 24 hours after bedtime dosing compared with 16 hours after morning dosing.

The effect of nighttime administration of anti-hypertensive drugs in nondipping patients has been tested in geographically distinct populations.^{49,50,51} Anti-hypertensive therapy delivered as an evening dose is highly effective at correcting the nondipping phenotype. Bedtime administration of valsartan, doxazosin (extended release), torasemid, or long-acting nifedipine improves efficacy and reduces side effects of anti-hypertensive treatment.⁵² These studies highlight the importance of evaluating the 24-hour BP profile as opposed to single, daytime office measurements. Although these results are promising, larger, more comprehensive trials are needed. A reduction in all-cause mortality would be a convincing outcome. A long-term study following thousands of subjects, the recently completed Monitorización Ambulatoria de la Presión Arterial y Eventos Cardiovasculares—Ambulatory Blood Pressure Monitoring and Cardiovascular Events (MAPEC) trial, was designed to determine whether restoring the dipper pattern using chronotherapy decreases the risk of cardiovascular disease.⁵³ Providing evidence for the use of chronotherapy in hypertension, the MAPEC results demonstrate that bedtime drug administration, compared to conventional upon-awakening therapy, was more effective at controlling BP and decreasing non-dipping, and resulted in significant reduction of cardiovascular morbidity and mortality.⁵⁴

Circadian Disturbances in Dialysis Patients

Melatonin is an important regulator of the circadian sleep-wake cycle. In healthy individuals, the pineal gland produces melatonin at night; light exposure suppresses melatonin production. The expected nighttime peak in melatonin levels is lost in patients undergoing hemodialysis, and decreased melatonin levels associate with more severe sleep disturbances in these pa-

tients. Interestingly, patients receiving nocturnal dialysis experienced the normal nighttime peak in melatonin and reported better sleep quality compared with daytime dialysis patients.⁵⁵ A recent study in patients with chronic kidney disease (CKD) found that melatonin amplitude decreases with advancing renal disease, emphasizing the need for further investigation into circadian mechanisms in CKD patients.⁵⁵

Patients undergoing dialysis treatment are more prone to sleep disturbances compared with the general population, resulting in a negative impact on overall health and quality of life. Nondipping CKD patients seem to have poor sleep quality.⁵⁶ Circadian sleep-wake disturbances are common in ESRD patients.⁵⁷ Renal disease and dialysis treatment may contribute to the etiology of sleep disturbances in dialysis patients independently of each other. Up to 80% of ESRD patients have reported subjective sleep problems. Daytime sleepiness is increased by dialysis, and this effect is the result of several factors, including elevated body temperature during treatment and the physical and emotional stress caused by the procedure. Likewise, sleep disturbances are a common side effect of medications prescribed to ESRD patients, including β -blockers and benzodiazepines. Several treatments aimed at resynchronizing the sleep-wake rhythm in hemodialysis patients result in some level of sleep improvement.⁵⁷ These include a switch to nocturnal hemodialysis, lowering the temperature of the dialyzate, exercise during dialysis, administration of melatonin, or exogenous erythropoietin treatment. Bright light therapy might also benefit hemodialysis patients with circadian sleep disruption.⁵⁷

Circadian Influence on Renal Function

In addition to a role for the kidney in maintaining proper BP rhythms, renal function oscillates in a circadian manner with daily fluctuations in renal blood flow and GFR⁵⁸ and the excretion of electrolytes such as sodium and potassium.⁵⁹ Likewise, urinary excretion of phosphate, magnesium, and

acid oscillates with a circadian pattern.^{60,61} Although these clinical observations have been well established, the underlying molecular mechanisms are unclear.

MOLECULAR EVIDENCE FOR THE ROLE OF A CIRCADIAN CLOCK IN THE KIDNEY

Transcriptional Regulation of Renal Gene Expression by the Circadian Clock

A growing number of genes are regulated by transcriptional mechanisms of the circadian clock. Many clock-controlled genes have been identified in the kidney through either gene expression profiling or candidate gene approaches (Table 1). The term “clock-controlled gene” is used here to describe genes that exhibit rhythmic expression. Most of the genes listed in Table 1 have only recently been linked to the circadian clock, and it remains to be determined whether circadian clock proteins interact with E-box elements in the promoters of these genes.

These genes encode products that range from transcription regulators⁶² to cell junction proteins.^{63,64} Although the implications of clock-mediated regulation of these genes are not yet clear, it is interesting that the function of the transcription repressor, Kid-1 (kidney, ischemia, developmentally-regulated gene 1),⁶⁵ is linked to regulation of extracellular signal-regulated kinases,⁶⁶ providing an intriguing link between a clock-controlled gene and signal transduction in the kidney. Furthermore, the rhythmic expression of E-cadherin and claudin-4 seemed to parallel the circadian changes observed in sodium excretion.⁶³

The circadian clock gene *Period 1* (*Per1*) was identified as a novel aldosterone target in a murine inner medullary collecting duct cell line and was the most highly induced transcript in the entire study.⁶⁷ *Per1* contributes to the basal and aldosterone-dependent transcription of *Scnn1a*, which encodes the rate-limiting subunit of the epithelial sodium channel.⁶⁸ *Scnn1a* expression is reduced in the renal medulla of *Per1* null mice. *Per1*-

Table 1. Clock-controlled genes in the kidney

Gene	Function	RNA Source	Reference
<i>Dec1</i>	bHLH transcription factor	Whole kidney	59
<i>Dec2</i>	bHLH transcription factor	Whole kidney	59
<i>Npas2</i>	bHLH transcription factor	Whole kidney	59
<i>Dbp</i>	Albumin Dsite binding protein	Whole kidney	59
<i>Cldn4</i>	Claudin 4, Tight junction protein	Whole kidney	60
<i>E-cadherin</i>	Adherens junctions	Whole kidney	60
<i>Kid-1</i>	Zn finger transcription repressor	Whole kidney	63
<i>Cldn8</i>	Claudin 8, Tight junction protein	DCT, CNT	61
<i>Mapre2</i>	Microtubule associated protein	DCT, CNT, CCD, whole kidney	61
<i>Ptges</i>	Prostaglandin E synthase	DCT, CNT	61
<i>Tfrc</i>	Transferrin receptor	DCT, CNT, CCD, whole kidney	61

bHLH, basic helix-loop-helix; DCT, distal convoluted tubule; CNT, connecting tubule; CCD, cortical collecting duct.

null mice excrete more urinary sodium than wild-type mice, although the mechanism of this effect is unknown. The apparent circadian expression of *Scnn1a* is also altered in mice lacking all three *Period* genes compared with wild-type mice. Given the critical role of the rate-limiting subunit of the epithelial sodium channel in sodium transport and BP control, these results implicate the clock in the mechanism underlying the known daily fluctuations in sodium excretion and BP.

Many renal transport genes have been identified as clock-controlled genes (Table 2). NHE3 was the first transporter in the kidney to be identified as a target of the clock transcription mechanism.⁶⁹ mRNA encoding *NHE3* is expressed in a circadian manner in wild-type rodents, but rhythmic expression is blunted in *Cry1/Cry2*-null mice. A specific E-box response element is required for Bmal1/Clock-mediated transactiva-

tion of *NHE3* promoter activity. Consistent with this observation is a recent report describing the presence of an E-box in the *Scnn1a* promoter that is bound by Clock and Per1.⁷⁰ Together these studies provide direct molecular evidence for regulation of transport gene expression by the circadian clock.

In the first study of its kind, Zuber *et al.*⁶⁴ used microarray analysis to profile the expression of circadian genes in microdissected distal nephron and collecting duct segments over a 24-hour period. Hundreds of putative clock-controlled genes were identified. Circadian expression of selected genes was confirmed in independent samples, and these genes are included in Tables 1 and 2. These novel clock targets encode moieties ranging from known regulators of sodium transport to critical regulators of water balance. Many of the genes listed in Table 2 are expressed in principal cells of the cortical collecting duct, and the products of these genes contribute to so-

dium and water transport (Figure 2). Further study will likely identify additional clock-controlled genes, providing additional insight into the mechanism by which the circadian clock regulates water and electrolyte transport in the kidney.

Rodent Models of Circadian

Disorganization

Casein kinase I ϵ -mediated phosphorylation controls stability of the Period proteins. *tau* mutant hamsters have a gain-of-function mutation in casein kinase I ϵ and display a shortened circadian period. Heterozygous *tau* mutants display a severe cardiorenal phenotype characterized by cardiomyopathy, hypertrophy, cardiac fibrosis, and early death⁷¹; renal dysfunction is manifested as proteinuria, tubular dilation, glomerular ischemia, and cellular apoptosis. SCN ablation in young adult *tau* mutant hamsters rescues the cardiac hypertrophy phenotype. Moreover, the cardiorenal phenotype is reversed and longevity is restored when the *tau* mutants are maintained on a shorter 22-hour light/dark cycle.

The mouse *renin* transgenic rat [*TGR(mREN2)27*] is also a well-characterized model of hypertension. These animals have an inverted circadian BP profile and consequent end-organ damage.⁷² *TGR* rats exhibit a profound circadian phenotype in which the normal circadian pattern of core clock gene expression, signal transduction pathways, and sympathetic nervous system activity is altered severely.⁷³ Consistent with human studies discussed above, the renin-angiotensin-aldosterone system contributes to maintenance of circadian rhythms in rodents.

Reports of BP phenotypes in rodents

Table 2. Clock-controlled transport genes in the kidney

Gene	Function	RNA Source	Reference
<i>Slc9a3</i> (NHE3)	Sodium/hydrogen exchange	Whole kidney	66
<i>Gilz</i>	Leucine zipper protein/regulation of sodium transport	DCT, CNT, CCD. Whole kidney	61
<i>Usp2</i>	Ubiquitin specific protease/regulation of sodium transport	DCT, CNT, CCD. Whole kidney	61
<i>V1aR</i>	Vasopressin receptor/regulation of water balance	DCT, CNT, CCD. Whole kidney	61
<i>V2R</i>	Vasopressin receptor/regulation of water balance	DCT, CNT, CCD. Whole kidney	61
<i>Slc6a6</i>	Taurine transporter	CCD	61
<i>Slc6a9</i>	Glycine transporter	DCT/CNT	61
<i>Aqp2</i>	Water channel	CCD	61
<i>Aqp4</i>	Water channel	CCD	61
<i>Scnn1a</i> (α ENaC)	Alpha subunit of epithelial sodium channel	Cortex, outer medulla and inner medulla	65

DCT, distal convoluted tubule; CNT, connecting tubule; CCD, cortical collecting duct.




Figure 2. Mechanisms of sodium, potassium, chloride, and water transport in a cortical collecting duct principal cell. Proteins denoted by the symbol are the products of genes that are expressed in an apparent circadian pattern. Na⁺, sodium; K⁺, potassium; Cl⁻, chloride; H₂O, water; ENaC, epithelial sodium channel; GILZ, glucocorticoid-induced leucine zipper protein; Usp2, ubiquitin-specific protease 2; SGK1, serum and glucocorticoid-regulated kinase; ET-1, endothelin-1; Nedd4-2, neural precursor cell expressed, developmentally downregulated gene 4-like; V1aR, vasopressin 1a receptor; V2R, vasopressin 2 receptor.

with circadian clock disruption suggest that the clock is critical for cardiovascular function. Whereas *Clock*-null mice maintain a normal 24-hour rhythm of BP, the average mean arterial pressure and mean systolic BP were significantly lower in these mice compared with wild type.⁶⁴ These mice display altered rhythms in urinary sodium excretion and a mild diabetes insipidus.

When maintained on a standard 12-hour light/dark cycle, *Per2* mutant mice exhibit decreased 24-hour diastolic BP, increased heart rate, and a decreased difference between day and night BP.⁷¹ Under constant darkness, wild-type mice maintained normal 24-hour rhythms in BP, activity, and heart rate, but *Per2* mutant mice experienced a shortened circadian period.

Salt-sensitive hypertension was observed in *Cry1/Cry2* knockout mice.⁷⁵ El-

evated plasma aldosterone levels were observed in these mice, leading the investigators to perform microarray analysis of adrenal glands from *Cry1/Cry2*-null mice compared with wild type. *Hsd3b6*, a dehydrogenase-isomerase in the aldosterone synthesis pathway, was identified as a highly overexpressed gene in null mice. Increased activity of this enzyme was recorded in *Cry1/Cry2* knockout mice and was linked to the observed salt-sensitive hypertension. Importantly, this study identified a putative target for interventional therapy in hypertensive patients. Given that the HSD3B6 enzyme catalyzes a relatively early reaction in the steroid hormone synthesis pathway (pregnenolone to progesterone), it will be interesting to see what other steroid hormones are elevated in these mice and how this defect influences the long-term health of these circadian mutant animals.

THE FUTURE

A critical issue is what proportion of circadian fluctuations in renal function is caused by the influence of the central clock in the SCN versus an intrinsic clock in the kidney alone. Renal tissue explants from *Per2/luciferase* transgenic mice oscillate in culture, and this effect is maintained after SCN ablation.¹⁰ Uncoupling of the peripheral clocks from the central clock by food restriction is another way to address this issue. Reversal of the light/dark cycle and the feeding schedule causes a phase shift in the expression of clock genes in rat kidney.⁷⁶ *Per1* and *Clock* appeared to be the most sensitive to these changes. An important tool in determining the role of the clock in individual tissues is the generation of tissue specific null mice. Indeed, pancreas-deficient *Bmal1* mice develop diabetes mellitus,⁷⁷ and knockout of *Clock* in cardiomyocytes alters the normal circadian rhythm of cardiac output, heart rate, and BP.⁷ Future studies using kidney-deficient clock genes will be critical to our understanding of how the circadian clock regulates renal function.

In addition to the transcriptional and post-translational regulation of the clock mechanism discussed above, microRNAs (miRNAs), which regulate mRNA stability and therefore protein expression, may play a role in the modulation of circadian rhythms.⁷⁸ In mammalian cell models, miRNA-192/194 regulates the expression of the *Period* gene family.⁷⁹ Overexpression of this miRNA causes a shortened circadian period. Very little is known about post-translational control of clock proteins in the kidney,⁸⁰ and the role of miRNAs in the renal circadian clock has not been explored to date. These dynamic processes likely allow fine-tuning of the clock mechanism in a tissue-specific manner.

CONCLUSIONS

Discerning the role of the circadian clock in the kidney has important implications for the design of novel therapies and improvement of existing treatments for renal disease. Numerous trials showed that chronotherapy in the treatment of nondippers is effective in re-

storing the normal 24-hour rhythm of BP in many patients. Improved use of 24-hour ambulatory BP monitoring could increase identification of nondippers that may benefit from nighttime administration of anti-hypertensive medications. Nighttime dialysis may benefit patients experiencing circadian disruption. To identify those patients most likely to benefit from chronotherapeutic intervention, we must gain a more complete understanding of the mechanism by which the circadian clock regulates renal function.

DISCLOSURES

We thank Dr. Charles Wingo for helpful discussions. This work was supported by Grant K01DK085193 (to M.L.G.).

REFERENCES

- Pons M, Cambar J, Waterhouse JM: Renal hemodynamic mechanisms of blood pressure rhythms. *Ann NY Acad Sci* 783: 95–112, 1996
- Manchester RC: The diurnal rhythm in water and mineral exchange. *J Clin Invest* 12: 995–1008, 1933
- Dyer AR, Martin GJ, Burton WN, Levin M, Stamler J: Blood pressure and diurnal variation in sodium, potassium, and water excretion. *J Human Hypertens* 12: 363–371, 1998
- Goldman R: Studies in diurnal variation of water and electrolyte excretion: Nocturnal diuresis of water and sodium in congestive cardiac failure and cirrhosis of the liver. *J Clin Invest* 30: 1191–1199, 1951
- Reppert SM, Weaver DR: Coordination of circadian timing in mammals. *Nature* 418: 935–941, 2002
- Albrecht U, Eichele G: The mammalian circadian clock. *Curr Opin Genet Develop* 13: 271–277, 2003
- Duguay D, Cermakian N: The crosstalk between physiology and circadian clock proteins. *Chronobiol Int* 26: 1479–1513, 2009
- Vollmers C, Gill S, DiTacchio L, Pulivarthy SR, Le HD, Panda S: Time of feeding and the intrinsic circadian clock drive rhythms in hepatic gene expression. *Proc Natl Acad Sci USA* 106: 21453–21458, 2009
- Dibner C, Schibler U, Albrecht U: The mammalian circadian timing system: Organization and coordination of central and peripheral clocks. *Annu Rev Physiol* 72: 517–549, 2010
- Yoo SH, Yamazaki S, Lowrey PL, Shimomura K, Ko CH, Buhr ED, Slepka SM, Hong HK, Oh WJ, Yoo OJ, Menaker M, Takahashi JS: PERIOD2::LUCIFERASE real-time reporting of circadian dynamics reveals persistent circadian oscillations in mouse peripheral tissues. *Proc Natl Acad Sci USA* 101: 5339–5346, 2004
- Guo H, Brewer JM, Champhekar A, Harris RB, Bittman EL: Differential control of peripheral circadian rhythms by suprachiasmatic-dependent neural signals. *Proc Natl Acad Sci USA* 102: 3111–3116, 2005
- Guo H, Brewer JM, Lehman MN, Bittman EL: Suprachiasmatic regulation of circadian rhythms of gene expression in hamster peripheral organs: Effects of transplanting the pacemaker. *J Neurosci* 26: 6406–6412, 2006
- Martino TA, Sole MJ: Molecular time: An often overlooked dimension to cardiovascular disease. *Circ Res* 105: 1047–1061, 2009
- Rudic RD: Time is of the essence: Vascular implications of the circadian clock. *Circulation* 120: 1714–1721, 2009
- Rudic RD, Fulton DJ: Pressed for time: The circadian clock and hypertension. *J Appl Physiol* 107: 1328–1338, 2009
- Maury E, Ramsey KM, Bass J: Circadian rhythms and metabolic syndrome: From experimental genetics to human disease. *Circ Res* 106: 447–462, 2010
- Hoogerwerf WA: Role of clock genes in gastrointestinal motility. *Am J Physiol* 299: G549–G555, 2010
- White WB: Ambulatory blood pressure monitoring: Dippers compared with non-dippers. *Blood Press Monit* 5[Suppl 1]: S17–S23, 2000
- Routledge FS, McFetridge-Durdle JA, Dean CR: Night-time blood pressure patterns and target organ damage: A review. *Can J Cardiol* 23: 132–138, 2007
- Hermida RC, Ayala DE, Portaluppi F: Circadian variation of blood pressure: The basis for the chronotherapy of hypertension. *Adv Drug Deliv Rev* 59: 904–922, 2007
- Garcia-Ortiz L, Gomez-Marcos MA, Martin-Moreiras J, Gonzalez-Elena LJ, Recio-Rodriguez JI, Castano-Sanchez Y, Grandes G, Martinez-Salgado C: Pulse pressure and nocturnal fall in blood pressure are predictors of vascular, cardiac and renal target organ damage in hypertensive patients (LOD-RISK study). *Blood Press Monit* 14: 145–151, 2009
- Takakuwa H, Shimizu K, Izumiya Y, Kato T, Nakaya I, Yokoyama H, Kobayashi K, Ise T: Dietary sodium restriction restores nocturnal reduction of blood pressure in patients with primary aldosteronism. *Hypertens Res* 25: 737–742, 2002
- Williams D, Croal B, Furnace J, Ross S, Witte K, Webster M, Critchen W, Webster J: The prevalence of a raised aldosterone-renin ratio (ARR) among new referrals to a hypertension clinic. *Blood Pressure* 15: 164–168, 2006
- Polonia J, Diogo D, Caupers P, Damasceno A: Influence of two doses of irbesartan on non-dipper circadian blood pressure rhythm in salt-sensitive black hypertensives under high salt diet. *J Cardiovasc Pharmacol* 42: 98–104, 2003
- Uzu T, Kimura G: Diuretics shift circadian rhythm of blood pressure from nondipper to dipper in essential hypertension. *Circulation* 100: 1635–1638, 1999
- Uzu T, Fujii T, Nishimura M, Kuroda S, Nakamura S, Inenaga T, Kimura G: Determinants of circadian blood pressure rhythm in essential hypertension. *Am J Hypertens* 12: 35–39, 1999
- Fukuda M, Goto N, Kimura G: Hypothesis on renal mechanism of non-dipper pattern of circadian blood pressure rhythm. *Medical Hypotheses* 67: 802–806, 2006
- Portaluppi F, Montanari L, Massari M, Di Chiara V, Capanna M: Loss of nocturnal decline of blood pressure in hypertension due to chronic renal failure. *Am J Hypertens* 4: 20–26, 1991
- Gatzka CD, Schobel HP, Klingbeil AU, Neumayer HH, Schmieder RE: Normalization of circadian blood pressure profiles after renal transplantation. *Transplantation* 59: 1270–1274, 1995
- Wadei HM, Am H, Taler SJ, Cosio FG, Griffin MD, Grande JP, Larson TS, Schwab TR, Stegall MD, Textor SC: Diurnal blood pressure changes one year after kidney transplantation: Relationship to allograft function, histology, and resistive index. *J Am Soc Nephrol* 18: 1607–1615, 2007
- Kimura G, Dohi Y, Fukuda M: Salt sensitivity and circadian rhythm of blood pressure: The keys to connect CKD with cardiovascular events. *Hypertens Res* 33: 515–520, 2010
- Timio M, Venanzi S, Lolli S, Lippi G, Verdura C, Monarca C, Guerrini E: “Non-dipper” hypertensive patients and progressive renal insufficiency: A 3-year longitudinal study. *Clin Nephrol* 43: 382–387, 1995
- Agarwal R, Light RP: GFR, proteinuria and circadian blood pressure. *Nephrol Dial Transplant* 24: 2400–2406, 2009
- Ohdo S: Chronotherapeutic strategy: Rhythm monitoring, manipulation and disruption. *Adv Drug Deliv Rev* 62: 859–875, 2010
- Takahashi JS, Hong HK, Ko CH, McDearmon EL: The genetics of mammalian circadian order and disorder: Implications for physiology and disease. *Nat Rev Genet* 9: 764–775, 2008
- Innominato PF, Levi FA, Bjarnason GA: Chronotherapy and the molecular clock: Clinical implications in oncology. *Adv Drug Deliv Rev* 62: 979–1001, 2010
- Rana S, Mahmood S: Circadian rhythm and its role in malignancy. *J Circadian Rhythms* 8: 3, 2010
- Glass-Marmor L, Paperna T, Ben-Yosef Y, Miller A: Chronotherapy using corticosteroids for multiple sclerosis relapses. *J Neurol Neurosurg Psychiatr* 78: 886–888, 2007
- Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E, Jeka S, Krueger K, Szechinski J, Alten R: Targeting pathophysiological rhythms: Prednisone chronotherapy shows sustained efficacy in rheumatoid arthritis. *Ann Rheum Dis* 69: 1275–1280, 2010
- Smolensky MH, Lemmer B, Reinberg AE:

- Chronobiology and chronotherapy of allergic rhinitis and bronchial asthma. *Adv Drug Deliv Rev* 59: 852–882, 2007
41. Kanat M: Is daytime insulin more physiologic and less atherogenic than bedtime insulin? *Med Hypotheses* 68: 1228–1232, 2007
 42. Portaluppi F, Hermida RC: Circadian rhythms in cardiac arrhythmias and opportunities for their chronotherapy. *Adv Drug Deliv Rev* 59: 940–951, 2007
 43. Portaluppi F, Lemmer B: Chronobiology and chronotherapy of ischemic heart disease. *Adv Drug Deliv Rev* 59: 952–965, 2007
 44. Smolensky MH, Hermida RC, Ayala DE, Tiseo R, Portaluppi F: Administration-time-dependent effects of blood pressure-lowering medications: Basis for the chronotherapy of hypertension. *Blood Press Monit* 15: 173–180, 2010
 45. Cuspidi C, Vaccarella A, Leonetti G, Sala C: Ambulatory blood pressure and diabetes: targeting nondipping. *Curr Diabet Rev* 6: 111–115, 2010
 46. Ernst ME: Nighttime blood pressure is the blood pressure. *Pharmacotherapy* 29: 3–6, 2009
 47. White WB: Relating cardiovascular risk to out-of-office blood pressure and the importance of controlling blood pressure 24 hours a day. *Am J Med* 121: S2–S7, 2008
 48. Hermida RC, Ayala DE: Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: Improved blood pressure control with bedtime dosing. *Hypertension* 54: 40–46, 2009
 49. Hermida RC, Ayala DE, Fernandez JR, Calvo C: Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. *Hypertension* 51: 69–76, 2008
 50. Minutolo R, Gabbai FB, Borrelli S, Scigliano R, Trucillo P, Baldanza D, Laurino S, Mascia S, Conte G, De Nicola L: Changing the timing of antihypertensive therapy to reduce nocturnal blood pressure in CKD: an 8-week uncontrolled trial. *Am J Kidney Dis* 50: 908–917, 2007
 51. Takeda A, Toda T, Fujii T, Matsui N: Bedtime administration of long-acting antihypertensive drugs restores normal nocturnal blood pressure fall in nondippers with essential hypertension. *Clin Exp Nephrol* 13: 467–472, 2009
 52. Simko F, Pechanova O: Potential roles of melatonin and chronotherapy among the new trends in hypertension treatment. *J Pineal Res* 47: 127–133, 2009
 53. Hermida RC: Ambulatory blood pressure monitoring in the prediction of cardiovascular events and effects of chronotherapy: Rationale and design of the MAPEC study. *Chronobiol Int* 24: 749–775, 2007
 54. Hermida RC, Ayala DE, Fernández JR: Influence of circadian time of hypertension treatment on cardiovascular risk: results of the MAPEC study. *Chronobiology Int* 8: 1629–1651, 2010
 55. Koch BC, Nagtegaal JE, Hagen EC, Wee PM, Kerkhof GA: Different melatonin rhythms and sleep-wake rhythms in patients on peritoneal dialysis, daytime hemodialysis and nocturnal hemodialysis. *Sleep Medicine* 11: 242–246, 2010
 56. Agarwal R, Light RP: Physical activity and hemodynamic reactivity in chronic kidney disease. *Clin J Am Soc Nephrol* 3: 1660–1668, 2008
 57. Koch BC, Nagtegaal JE, Kerkhof GA, ter Wee PM: Circadian sleep-wake rhythm disturbances in end-stage renal disease. *Nat Rev* 5: 407–416, 2009
 58. Vagnucci AH, Shapiro AP, McDonald RH Jr: Effects of upright posture on renal electrolyte cycles. *J Appl Physiol* 26: 720–731, 1969
 59. Moore-Ede MC: Physiology of the circadian timing system: Predictive versus reactive homeostasis. *Am J Physiol* 250: R737–R752, 1986
 60. Min HK, Jones JE, Flink EB: Circadian variations in renal excretion of magnesium, calcium, phosphorus, sodium, and potassium during frequent feeding and fasting. *Fed Proc* 25: 917–921, 1966
 61. Cameron MA, Baker LA, Maalouf NM, Moe OW, Sakhaee K: Circadian variation in urine pH and uric acid nephrolithiasis risk. *Nephrol Dial Transplant* 22: 2375–2378, 2007
 62. Noshiro M, Furukawa M, Honma S, Kawamoto T, Hamada T, Honma K, Kato Y: Tissue-specific disruption of rhythmic expression of Dec1 and Dec2 in clock mutant mice. *J Biol Rhythms* 20: 404–418, 2005
 63. Yamato M, Ito T, Iwatani H, Yamato M, Imai E, Rakugi H: E-cadherin and claudin-4 expression has circadian rhythm in adult rat kidney. *J Nephrol* 23: 102–110, 2010
 64. Zuber AM, Centeno G, Pradervand S, Nikolaeva S, Maquelin L, Cardinaux L, Bonny O, Firsov D: Molecular clock is involved in predictive circadian adjustment of renal function. *Proc Natl Acad Sci USA*, 106: 16523–16528, 2009
 65. Witzgall R, O'Leary E, Gessner R, Ouellette AJ, Bonventre JV: Kid-1, a putative renal transcription factor: Regulation during ontogeny and in response to ischemia and toxic injury. *Molec Cell Biol* 13: 1933–1942, 1993
 66. Yamato M, Ishida N, Iwatani H, Yamato M, Rakugi H, Ito T: Kid-1 participates in regulating ERK phosphorylation as a part of the circadian clock output in rat kidney. *J Receptor Signal Transduction Res* 29: 94–99, 2009
 67. Gumz ML, Popp MP, Wingo CS, Cain BD: Early transcriptional effects of aldosterone in a mouse inner medullary collecting duct cell line. *Am J Physiol* 285: F664–F673, 2003
 68. Gumz ML, Stow LR, Lynch IJ, Greenlee MM, Rudin A, Cain BD, Weaver DR, Wingo CS: The circadian clock protein Period 1 regulates expression of the renal epithelial sodium channel in mice. *J Clin Invest* 119: 2423–2434, 2009
 69. Saifur Rohman M, Emoto N, Nonaka H, Okura R, Nishimura M, Yagita K, van der Horst GT, Matsuo M, Okamura H, Yokoyama M: Circadian clock genes directly regulate expression of the Na(+)/H(+) exchanger NHE3 in the kidney. *Kidney Int* 67: 1410–1419, 2005
 70. Gumz ML, Cheng K, Lynch IJ, Stow LR, Greenlee MM, Cain BD, Wingo CS: Regulation of α ENaC expression by the circadian clock protein period 1 in mpkCCDC14 cells. *Biochim Biophys Acta* 1799: 622–629, 2010
 71. Martino TA, Oudit GY, Herzenberg AM, Tata N, Koletar MM, Kabir GM, Belsham DD, Backx PH, Ralph MR, Sole MJ: Circadian rhythm disorganization produces profound cardiovascular and renal disease in hamsters. *Am J Physiol Regul Integr Comp Physiol* 294: R1675–R1683, 2008
 72. Witte K, Lemmer B: Development of inverse circadian blood pressure pattern in transgenic hypertensive TGR(mREN2)27 rats. *Chronobiol Int* 16: 293–303, 1999
 73. Lemmer B, Witte K, Enzlinger H, Schiffer S, Hauptfleisch S: Transgenic TGR(mREN2)27 rats as a model for disturbed circadian organization at the level of the brain, the heart, and the kidneys. *Chronobiol Int* 20: 711–738, 2003
 74. Vukolic A, Antic V, Van Vliet BN, Yang Z, Albrecht U, Montani JP: Role of mutation of the circadian clock gene Per2 in cardiovascular circadian rhythms. *Am J Physiol Regul Integr Comp Physiol*, 298: R627–R634, 2010
 75. Doi M, Takahashi Y, Komatsu R, Yamazaki F, Yamada H, Haraguchi S, Emoto N, Okuno Y, Tsujimoto G, Kanematsu A, Ogawa O, Todo T, Tsutsui K, van der Horst GT, Okamura H: Salt-sensitive hypertension in circadian clock-deficient Cry-null mice involves dysregulated adrenal Hsd3b6. *Nat Med* 16: 67–74, 2010
 76. Wu T, Ni Y, Dong Y, Xu J, Song X, Kato H, Fu Z: Regulation of circadian gene expression in the kidney by light and food cues in rats. *Am J Physiol Regul Integr Comp Physiol*, 298: R635–R641, 2010
 77. Marcheiva B, Ramsey KM, Buhr ED, Kobayashi Y, Su H, Ko CH, Ivanova G, Omura C, Mo S, Vitaterna MH, Lopez JP, Philipson LH, Bradfield CA, Crosby SD, Jebailey L, Wang X, Takahashi JS, Bass J: Disruption of the clock components CLOCK and BMAL1 leads to hypoinulinaemia and diabetes. *Nature* 466: 627–631, 2010
 78. Pegoraro M, Tauber E: The role of microRNAs (miRNA) in circadian rhythmicity. *J Genet* 87: 505–511, 2008
 79. Nagel R, Clijsters L, Agami R: The miRNA-192/194 cluster regulates the Period gene family and the circadian clock. *FEBS J* 276: 5447–5455, 2009
 80. Silva CM, Sato S, Margolis RN: No time to lose: Workshop on circadian rhythms and metabolic disease. *Genes Dev* 24: 1456–1464, 2010